Ricerca avanzata

Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2014 Dicembre;26(4) > Minerva Biotecnologica 2014 Dicembre;26(3):309-13

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

Periodicità: Trimestrale

ISSN 1120-4826

Online ISSN 1827-160X

 

Minerva Biotecnologica 2014 Dicembre;26(3):309-13

 ORIGINAL ARTICLES

Combined use of Xunxi No. 1 and radiotherapy have clinical benefits in stage Ia-IIb cervical cancer patients with high-risk human papilloma virus infection

Xu X. 1, Zhang B. 2, Hao L. 2, Gu J. 2, Liu L. 3, Wang X. 4, Wu M. 5, Zhang P. 6, Cheng H. 5

1 Department of Gynaecology and Obstetrics, Xuzhou Traditional Chinese Medicine Hospital, Xuzhou 221009, China;
2 Department of Gynaecology and Obstetrics, The Affiliated School of Clinical Medicine, Xuzhou Medical College, Xuzhou, China;
3 Department of Radiotherapy, Xuzhou City Central Hospital, Xuzhou, China;
4 Pathology Department, Xuzhou Traditional Chinese Medicine Hospital, Xuzhou, China;
5 Department of Traditional Chinese Medicine, First Clinical College, Nanjing University of Traditional Chinese Medicine, Nanjing, China;
6 Department of Traditional Chinese Medicine, Xuzhou City Central Hospital, Xuzhou, China

AIM: We determined the clinical benefit of Chinese medicinal intervention (Xunxi No. 1) in cervical cancer (CC) patients with high-risk human papilloma virus (HR-HPV) infection undergoing radiotherapy (RT).
METHODS: Eighty stage Ia-IIb CC patients receving primary RT were randomly-and-equally divided into treatment (RT+Xunxi No. 1 for 20 days) and control (RT alone) groups. Expression of the HR-HPV (HPV16/18) was detected by in-situ hybridization (ISH) before and after treatment. The 5-year disease-free survival and pelvic lymphnode metastasis (> 0.9 cm diameter shown by CT) rates were determined.
RESULTS: We found that the HR-HPV positivity rate decreased (37.5-67.5%) significantly (P<0.05) in treatment group while the reduction in control group (65.0 – 72.5%) was non-significant. The 3-year disease-free survival rate in treatment group was better than control group (33/40 vs. 27/40). Notably, the difference in two groups was statistically significant (P<0.05) regarding the 5-year disease-free survival (65.0% vs. 42.5%) and pelvic lymphnode metastasis rate (7.5% vs. 25.0%). It was therefore concluded that the early-stage RT with Xunxi No.1 lowered the HPV positivity rate in CC.
CONCLUSION: The higher 5-year disease-free survival rate and the lower pelvic lymphnode metastasis rate in treatment group as compared with control group suggest that Xunxi No.1 clinically benefits CC patients.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina